Montané E, Arellano AL, Sanz Y, Roca J, Farré M. Drug-related deaths in hospital inpatients: a retrospective cohort study. Br J Clin Pharmacol 2017;84:1. [Ref.ID 102184]

Anónimo. Inzitan® (dexametasona, tiamina, cianocobalamina, lidocaína): suspensión de comercialización. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) 2017:30 de noviembre. [Ref.ID 102154]

Pinto RZ, Verwoerd AJH, Koes BW. Which pain medications are effective for sciatica (radicular leg pain)?. BMJ 2017;359:j4248. [Ref.ID 102095]

Patel P, Leeder JS, Piquette-Miller M, Dupuis LL. Aprepitant and fosaprepitant drug interactions: a systematic review. Br J Clin Pharmacol 2017;83:2148-62. [Ref.ID 102081]

Anónimo. Daratumumab en monothérapie et myélome multiple en rechute et réfractaire. Prescrire 2017;37:491-3. [Ref.ID 102005]

DREAMS Trial Collaborators and West Midlands Research Collaborative. Dexamethasone versus standard treatment for postoperative nausea and vomiting in gastrointestinal surgery: randomised controlled trial (DREAMS Trial). BMJ 2017;357:j1455. [Ref.ID 101540]

Anónimo. Aprépitant chez les enfants. Prescrire 2017;37:5-7. [Ref.ID 101361]

Anónimo. Encéphalopathies postérieures réversibles d'origine médicamenteuse. Prescrire 2016;36:907-10. [Ref.ID 101007]

Anónimo. Carfilzomib et myélome multiple. Prescrire 2016;36:885-6. [Ref.ID 101002]

Anónimo. FDA approves use of daratumumab in combination with standard-of-care regimens to treat relapsed multiple myeloma. DIA Daily 2016:2. [Ref.ID 100977]

Rajkumar SV, Kyle RA. Progress in myeloma - A monoclonal breakthrough. N Engl J Med 2016;375:1390-2. [Ref.ID 100825]

Dimopoulos MA, Oriol A, Nahi H, SAn-Miguel J, Bahlis NJ, Usmani SZ, Rabin N, Orlowski RZ, Komamicki M, Suzuki K, Plesner T, Yoon S-S, Yehuda DB, Richardson PG, Goldschmidt H, Reece D, Lisby S, Khokhar NZ, O'Rourke L, Chiu C, Qin X, Guckert M, Ahmadi T, Moreau P, for the POLLUX Investigators. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 2016;375:1319-31. [Ref.ID 100824]

Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, Spicka I, Hungria V, Munder M, Mateos MV, Mark TM, Schecter J, Amin H, Qin X, Deraedt W, Ahmadi T, Spencer A, Sonneveld P, for the CASTOR Investigators. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med 2016;375:754-66. [Ref.ID 100717]

Anónimo. Patients enceintes gênées par une conjonctivite allergique. Prescrire 2016;36:521-5. [Ref.ID 100557]

Anónimo. Lénalidomide et myélome multiple en 1re ligne. Prescrire 2016;36:415-6. [Ref.ID 100543]

Anónimo. Panobinostat. Prescrire 2016;36:413-4. [Ref.ID 100542]

McCarthy M. Newer drugs for refractory and relapsed multiple myeloma are effective but costly, review finds. BMJ 2016;353:i2725. [Ref.ID 100423]

Moreau P, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, Sandhu I, Ganly P, Baker BW, Jackson SR, Stoppa A-M, Simpson DR, Gimsing P, Palumbo A, Garderet L, Cavo M, Kumar S, Touzeau C, Buadi FK, Laubach JP, Berg DT, Lin J, Di Bacco A, Hui A-M, van de Velde H, Richardson PG, for the TOURMALINE-MM1 Study Group. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 2016;374:1621-34. [Ref.ID 100245]

Anónimo. Pomalidomida ( Imnovid®): riesgo de reactivación del virus de la hepatitis B. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) 2016:abril. [Ref.ID 100160]

Lonial S, Dimopoulos M, Palumbo A, White D, Grosicki S, Spicka I, Walter-Croneck A, Moreau P, Mateos MV, Magen H, Belch A, Reece D, Beksac M, Spencer A, Oakervee H, Orlowski RZ, Taniwaki M, Röllig C, Einsele H, Wu KL, Singhal A, SAn-Miguel J, Matsumoto M, Katz J, Bleickardt E, Poulart V, Anderson KC, Richardson P, ELOQUENT-2 Investigators. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med 2015;373:621-31. [Ref.ID 99496]